Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vose

Showing results (481-490 of 891) with videos related to

Pageof 90
Sort By:
Cancer Immunology, Immunotherapy : CII|January 1, 1984
The human mixed lymphocyte-tumor cell interaction test. I. Positive autologous lymphocyte proliferative responses can be stimulated by tumor cells as well as by cells from normal tissuesE A Grimm, B M Vose, E W Chu, et al.
Global Change Biology|September 26, 2015
Forest biogeochemistry in response to droughtWilliam H Schlesinger, Michael C Dietze, Robert B Jackson, et al.
Bone Marrow Transplantation|February 1, 1991
The use of recombinant human granulocyte-macrophage colony stimulating factor for the treatment of delayed engraftment following high dose therapy and autologous hematopoietic stem cell transplantation for lymphoid malignanciesJ M Vose, P J Bierman, A Kessinger, et al.
Molecular Cancer Therapeutics|August 22, 2013
Novel treatment for mantle cell lymphoma including therapy-resistant tumor by NF-κB and mTOR dual-targeting approachNagendra K Chaturvedi, Rajkumar N Rajule, Ashima Shukla, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 18, 2014
Phase I/II study of bortezomib-BEAM and autologous hematopoietic stem cell transplantation for relapsed indolent non-Hodgkin lymphoma, transformed, or mantle cell lymphomaBasem M William, Mary S Allen, Fausto R Loberiza, et al.
Leukemia & Lymphoma|September 23, 2010
Association of number of follow-up providers with outcomes in survivors of hematologic malignanciesAnthony J Cannon, Deborah L Darrington, Helen E McIlvain, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 1, 1996
Hodgkin's disease following solid organ transplantationP J Bierman, J M Vose, A N Langnas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1993
High-dose chemotherapy and autologous hematopoietic stem-cell transplantation for aggressive non-Hodgkin's lymphomaJ M Vose, J R Anderson, A Kessinger, et al.
Leukemia & Lymphoma|January 7, 2009
Tumor-specific recombinant idiotype immunisation after chemotherapy as initial treatment for follicular non-Hodgkin lymphomaJohn M Timmerman, Julie M Vose, Debra K Czerwinski, et al.
British Journal of Haematology|December 6, 2008
The Stanford V regimen is effective in patients with good risk Hodgkin lymphoma but radiotherapy is a necessary componentJamil Y Abuzetun, Fausto Loberiza, Julie Vose, et al.
Pageof 90

Showing results (481-490 of 891) with videos related to

Sort By:
Pageof 90
Cancer Immunology, Immunotherapy : CII|January 1, 1984
The human mixed lymphocyte-tumor cell interaction test. I. Positive autologous lymphocyte proliferative responses can be stimulated by tumor cells as well as by cells from normal tissuesE A Grimm, B M Vose, E W Chu, et al.
Global Change Biology|September 26, 2015
Forest biogeochemistry in response to droughtWilliam H Schlesinger, Michael C Dietze, Robert B Jackson, et al.
Bone Marrow Transplantation|February 1, 1991
The use of recombinant human granulocyte-macrophage colony stimulating factor for the treatment of delayed engraftment following high dose therapy and autologous hematopoietic stem cell transplantation for lymphoid malignanciesJ M Vose, P J Bierman, A Kessinger, et al.
Molecular Cancer Therapeutics|August 22, 2013
Novel treatment for mantle cell lymphoma including therapy-resistant tumor by NF-κB and mTOR dual-targeting approachNagendra K Chaturvedi, Rajkumar N Rajule, Ashima Shukla, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 18, 2014
Phase I/II study of bortezomib-BEAM and autologous hematopoietic stem cell transplantation for relapsed indolent non-Hodgkin lymphoma, transformed, or mantle cell lymphomaBasem M William, Mary S Allen, Fausto R Loberiza, et al.
Leukemia & Lymphoma|September 23, 2010
Association of number of follow-up providers with outcomes in survivors of hematologic malignanciesAnthony J Cannon, Deborah L Darrington, Helen E McIlvain, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 1, 1996
Hodgkin's disease following solid organ transplantationP J Bierman, J M Vose, A N Langnas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1993
High-dose chemotherapy and autologous hematopoietic stem-cell transplantation for aggressive non-Hodgkin's lymphomaJ M Vose, J R Anderson, A Kessinger, et al.
Leukemia & Lymphoma|January 7, 2009
Tumor-specific recombinant idiotype immunisation after chemotherapy as initial treatment for follicular non-Hodgkin lymphomaJohn M Timmerman, Julie M Vose, Debra K Czerwinski, et al.
British Journal of Haematology|December 6, 2008
The Stanford V regimen is effective in patients with good risk Hodgkin lymphoma but radiotherapy is a necessary componentJamil Y Abuzetun, Fausto Loberiza, Julie Vose, et al.
Pageof 90